6.4 Communicating with Prescribers & Documenting Changes

6.4 Communicating with Prescribers & Documenting Changes

Quick Answer: If evaluation or clinical checks fail, contact the prescriber with a clear safety message, recommended action, and timeframe. Use a structured approach (SBAR-style), withhold supply when risk or legality is unresolved, document what was agreed, amend directions only through a lawful pathway, and escalate if patient safety remains at risk. Collaboration is professional — it is not rubber-stamping unsafe orders.

Dispensing competence includes interprofessional communication. Many Intern Written stems are decided not by drug monographs alone, but by whether you choose an appropriate communication and documentation pathway.

Why communication is part of Standard 3.2.3

You will regularly find:

• Missing prescription particulars
• Ambiguous doses
• Allergy conflicts
• Interaction or duplication problems
• Renal dose mismatches
• Patient reports that differ from the written plan
• Monitoring results that make the current dose unsafe

In each case, the pharmacist’s duty is to protect the patient and maintain a defensible record. Silence, guessing, or “the doctor will sort it later” after full supply is not acceptable when critical risk is present.

Professional assertiveness

Professional assertiveness sits between two failure modes:

Assertive language patterns:

• “I am calling because I have a safety concern about…”
• “The patient’s record shows… which conflicts with…”
• “My recommendation is to… Alternatives could include…”
• “I will withhold supply until we confirm…”

Avoid:

• “You made a mistake” as an opening (focus on the clinical issue)
• Hiding the concern in vague small talk until the end of the call
• Accepting an unsafe instruction solely because of hierarchy or time pressure

Hierarchy does not outrank patient safety or legal supply requirements. Specialists and senior medical staff can still receive appropriate pharmacist challenges when evidence supports concern.

SBAR-style communication

SBAR is widely used in healthcare handovers. Adapted for pharmacist–prescriber calls:

S — Situation

One sentence: who you are, who the patient is, and the immediate issue.

“This is Priya, pharmacist at Harbour Pharmacy, calling about Sam Lee’s new prescription for drug X — I have a concern about the dose given the recorded eGFR.”

B — Background

Brief relevant facts only: age, key conditions, current medicines, allergy, pregnancy status, what the script says, recent labs if known.

“Sam is 79 with CKD; eGFR was 28 last month. Regular medicines include an ACE inhibitor. The new script is full-dose drug X daily.”

A — Assessment

Your professional interpretation.

“At this renal function, AMH suggests a reduced dose / increased interval; full dose risks accumulation and toxicity. There is also additive renal risk with the NSAID on file.”

R — Recommendation

Specific ask and interim plan.

“I recommend reducing to [dose] and reviewing the NSAID. I am withholding full-dose supply for now. Can you confirm an amended dose today?”

Why SBAR helps in exams and practice: it forces prioritisation, reduces rambling, and makes the “what do you want the prescriber to do?” explicit — which is often what distinguishes a high-scoring action option.

Communication channels

• Phone for urgent clinical/legal blocks
• Secure messaging / e-prescription amendment pathways where available
• Written confirmation when changes are complex
• Avoid relying on the patient as the sole messenger for critical dose changes

When to withhold supply

Withholding (or delaying) supply is appropriate when:

1. Prescription is legally incomplete or inauthentic
2. Critical clinical risk is unresolved (severe allergy match, major interaction, apparent overdose, pregnancy contraindication, anticoagulant duplication)
3. S8/monitored medicine requirements are not met
4. Patient identity cannot be reasonably confirmed
5. Cold-chain or product integrity is compromised and no safe alternative stock exists
6. The patient refuses essential counselling for a high-risk medicine and cannot use it safely (context-dependent judgement)

Withholding is not abandonment. Explain the reason in plain language, assess interim risk (e.g. seizure medicines, insulin, transplant immunosuppressants), and escalate urgently to obtain a safe plan. For time-critical therapies, prioritise rapid prescriber contact and consider emergency legal pathways recognised in your jurisdiction only when they truly apply — do not invent emergency powers.

Partial information strategy

Sometimes you can supply an interim safe option after agreement (short quantity, reduced dose as amended, alternative agent). Never create a permanent therapy change without prescriber authority except where specific pharmacist prescribing/structured collaborative arrangements lawfully allow it.

Documenting interventions

If it is not documented, it is difficult to defend, hand over, or claim that care occurred. Document:

• Date/time and pharmacist identity
• Issue identified (legal and/or clinical)
• Information sources (patient report, eGFR value, allergy history, AMH check)
• Who was contacted (prescriber name/role) and how
• Advice given and options discussed
• Agreed outcome (amended dose, cancelled item, monitoring plan, no change with rationale)
• What was supplied (including partial/owing)
• Patient counselling points related to the change
• Follow-up actions (recall, lab check, next contact)

Keep records factual and professional. Avoid pejorative comments about the prescriber. Privacy rules still apply — document what is needed for care and accountability.

Agreed changes and amended directions

When the prescriber agrees to a change:

1. Confirm the new drug/strength/dose/quantity/duration clearly
2. Ensure the prescription record is amended through a lawful mechanism (new prescription, compliant electronic amendment, or jurisdiction-accepted annotation process — especially strict for S8)
3. Update the dispensing system so the label matches the agreed regimen
4. Destroy or quarantine incorrect labels/products prepared under the old directions
5. Counsel the patient on what changed and why, including old pack disposal if relevant
6. Communicate changes to other carers/facilities when appropriate (e.g. dose administration aid packing service, residential aged care)

Critical rule: do not permanently change a prescribed regimen based only on patient preference without prescriber involvement when the medicine is prescription-only and the change is clinically material. Do not “quietly” alter directions on the label while leaving the legal prescription and claim inconsistent.

Examples of acceptable vs unacceptable amendment practice

Escalation if patient safety risk persists

If the prescriber is uncontactable, dismissive without addressing the clinical evidence, or insists on a course you reasonably believe is seriously unsafe or illegal:

1. Re-state the concern with evidence and proposed safer alternatives
2. Withhold if legal/critical safety threshold is not met
3. Seek a second clinical opinion pathway appropriate to setting (another authorised prescriber involved in care, hospital team, senior pharmacist/clinical lead)
4. For suspected diversion, forgery, or criminality, follow legal reporting and non-supply obligations
5. For ongoing professional conduct concerns, understand Board notification pathways exist for serious risk — used judiciously, not as a first response to ordinary clinical disagreement
6. Document every step and the reason supply did or did not proceed

Escalation is about risk, not winning an argument.

Collaborative care mindset

Effective pharmacist–prescriber relationships improve outcomes:

• Share monitoring results and adherence barriers
• Offer practical alternatives (formulations, PBS-available strengths, simpler regimens)
• Acknowledge diagnostic uncertainty when you lack the full medical picture — ask for the missing piece rather than overclaiming
• Close the loop: after an agreed change, confirm the patient understands and that packing services/other pharmacies are not still supplying the old plan
• Respect scope: recommend and question; do not present recommendations as orders to medical colleagues, and do not accept illegal orders as “collaboration”

Collaboration includes the patient. Explain why you are contacting the doctor, what you are recommending, and what happens next. Patients who understand the safety reason are less likely to pressure unsafe supply.

Integrated communication workflow

1. Detect issue (legal evaluation or clinical check)
2. Decide urgency and whether interim partial supply is safe
3. Prepare SBAR facts and preferred options (AMH-supported)
4. Contact prescriber via appropriate channel
5. Agree plan or escalate
6. Lawfully amend prescription/records
7. Label, pack, counsel to the new plan
8. Document intervention and follow-up

Exam mindset

High-yield stems often offer four options: dispense as written; change label unilaterally; contact/withhold with structured recommendation; or ignore because “doctor knows best.” The best answer almost always preserves legal supply authority + patient safety + documentation, using assertive structured communication rather than silence or unilateral guesswork.